Mac-1 deficiency ameliorates pressure overloaded heart failure through inhibiting macrophage polarization and

Qiu-Yue Lin1, Wei-Jia Yu1, Jie Bai2

  • 1Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China.

Insights

Macrophage-1 antigen (Mac-1) deficiency ameliorates cardiac remodeling and dysfunction following pressure overload. Mac-1 knockout mice showed reduced heart failure, suggesting Mac-1 inhibition as a potential therapeutic strategy.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Pathology

Background:

  • Persistent pressure overload causes pathological cardiac hypertrophy, remodeling, and heart failure (HF).
  • Immune cell involvement and inflammation are key in cardiac remodeling pathogenesis.
  • Macrophage-1 antigen (Mac-1) regulates leukocyte migration and polarization, but its role in pressure overload-induced cardiac remodeling is unknown.

Purpose of the Study:

  • To investigate the role of Mac-1 in cardiac remodeling and heart failure induced by pressure overload.
  • To determine the effects of Mac-1 deficiency on cardiac function and pathology in response to transverse aortic constriction (TAC).

Main Methods:

  • Macrophage-1 antigen-knockout (KO) and wild-type (WT) mice underwent TAC for 6 weeks.
  • Cardiac function was assessed using echocardiography and pressure-volume loop analysis.
  • Cardiac remodeling, macrophage infiltration, and polarization were evaluated via histopathology and molecular techniques.

Main Results:

  • Mac-1 expression increased significantly in TAC-treated hearts.
  • Mac-1-KO mice exhibited significantly improved cardiac function and reduced hypertrophy, fibrosis, oxidative stress, and apoptosis compared to WT mice.
  • Mac-1 deficiency inhibited macrophage infiltration and M1 polarization, associated with altered NF-kB, STAT1, and STAT6 expression.

Conclusions:

  • Mac-1 deficiency confers protection against pathological cardiac remodeling and heart failure induced by pressure overload.
  • Inhibiting Mac-1 presents a potential therapeutic avenue for treating heart failure.